Kornimate/medical-research-clean huggingface dataset:
a study of bleximenib, venetoclax and azacitidine for treatment of participants with acute myeloid leukemia (aml)

Conditions: Leukemia, Myeloid, Acute

Summary: the purpose of this study is to assess how bleximenib and venetoclax (ven)+ azacitidine (aza) works as compared to placebo and ven+aza alone for the treatment of participants with acute myeloid leukemia (aml).


Eligibility criteria:
inclusion criteria: * be 18 years of age or older at the time of informed consent * previously untreated lysine n-methyltransferase 2a gene rearranged (kmt2ar) or nucleophosmin 1 gene mutated (npm1m) acute myeloid leukemia (aml) with greater than or equal to (\> or =) 10% bone marrow blasts per 2022 international consensus classification criteria * ineligible for intensive chemotherapy based on the following criteria: a) \>= 75 years of age and ineligible per physician's discretion, with eastern cooperative oncology group (ecog) performance status of 0-2, b) \>=18 to \ = 1 of the following comorbidities: i) ecog performance status of 2, ii) severe cardiac disorder, iii) severe pulmonary disorder, iv) renal impairment, v) comorbidity that, in the investigator's opinion, makes the participant unsuitable for intensive chemotherapy, which must be documented and approved by the sponsor before enrollment defined in the protocol * participants must have adequate hepatic and renal function * a female participant must agree not to be pregnant, breast-feed, plan to become pregnant and use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment * a male participant must agree to use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment * must sign an informed consent form indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study exclusion criteria: * diagnosis of acute promyelocytic leukemia (apl) * known active leukemic involvement of the central nervous system (cns) * recipient of solid organ transplant * any cardiac disorders such as heart attack, uncontrolled/unstable chest pain, congestive heart failure, uncontrolled or symptomatic irregular heartbeat, blockage of a blood vessel to brain, or transient ischemic (decreased oxygen in tissue) attack within 6 months of randomization * active infectious hepatitis * live, attenuated vaccine within 4 weeks of randomization * known allergies, hypersensitivity, or intolerance of bleximenib excipients
fmri guided tms enhancement of associative memory networks

Conditions: Epilepsy

Summary: this is a randomized, single-blinded, controlled phase 1 study to demonstrate feasibility and explore the neurophysiologic and clinical effects of repetitive transcranial magnetic stimulation (tms) interventions in epilepsy patients and healthy controls. the inclusion of a control group will be used to see whether epilepsy patients, who suffer from a higher degree of comorbid memory difficulty presumably from entorhinal-hippocampal dysfunction, can benefit from a tms intervention can benefit as much as a healthy matched population. investigators will also be looking at functional connectivity between the hippocampus and cortical regions


Eligibility criteria:
inclusion criteria: * fluent in english * right-handed * score at least 26 out of 30 on the montreal cognitive assessment (moca). healthy subjects will be matched to age, handedness, and education compared to epilepsy subjects. * must be able to provide informed consent. exclusion criteria: * any history of a neurological disorder * chronic or progressive medical condition * any history of severe traumatic brain injury or skull defect * metal or devices in the head, including neurostimulators of metal foreign bodies * any other implanted metal device, including pacemaker, spinal cord stimulator, vns. * any other ferromagnetic substance in the body (including tattoos, dental prosthetics, etc). * taking a medication which may lower the seizure threshold within the 4 weeks prior to the start of the study, including use of neuroleptic (esp. clozapine), antibiotic (penicillin, cephalosporins), and bronchodilating medications. * pregnancy

Keywords: cognitive dysfunction memory loss non-invasive transcranial magnetic stimulation (tms) rtms magstim rapid2
transcriptomic and biochemical changes during a migraine attack

Conditions: Migraine

Summary: despite the fact that migraine is a common disorder, the pathogenesis is still not fully elucidated. studying transcriptomic and biochemical changes during induced and spontaneous migraine-attacks will enhance our understanding and may point to new targets for drug development.

migraine is a common neurological disorder affecting approx. 16 % of the european population. despite the fact that migraine is a common disorder, the pathogenesis is still not sufficiently known. studying transcriptomic and biochemical changes during spontaneous migraine-attacks will greatly enhance our understanding of migraine mechanisms and may point to new targets for drug development. two blood samples (one for rna analysis and one for biochemical analysis) are taken on minimum 15 patient with migraine with aura and 15 patients with migraine without aura when they experience a spontaneous migraine attack. a second sample is taken 2 hours after treatment with subcutaneous sumatriptan. another two blood samples are taken when the patient has been migraine free for at least 5 days and had no other headache for at least 24 hours. a fourth set of blood samples are collected after a cold pressor test.

Eligibility criteria:
inclusion criteria: * migraine patients who meet ihs criteria for migraine with or without aura of both sexes, * 18-70 years, * 45-95 kg. exclusion criteria: * any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week), * serious somatic or psychiatric disease, * pregnancy, * and intake of daily medication (except oral contraceptives).
covid-19 pandemic and female sexual behavior

Conditions: Sexual Behavior; COVID

Summary: world health organization declared new sars-cov-2 infection a pandemic, and many states enacted strict, rules such as border closures, transportation restrictions and quarantine.many studies in the literature have described the relationship between mass disasters and female sexual behavior, but none have investigated the effect of sars-cov-2 pandemic on women's sexual attitude. the aim of this study is therefore to evaluate the effect of sars-cov-2 pandemic on female sexual behavior.

coronaviruses are a group of rna viruses that affect mainly the respiratory system and cause the common cold, fever, and coughs in mammals and birds. however, in some cases, coronaviruses are associated with more serious and lethal conditions, such as pneumonia, bronchitis, and severe acute respiratory syndrome. a novel coronavirus (sars-cov-2) originating from wuhan, china led to a global health crisis. at the time of writing, sars-cov-2 infected more than two million, resulting in almost 180.000 deaths. world health organization declared new sars-cov-2 infection a pandemic, and many states enacted strict, rules such as border closures, transportation restrictions, and quarantine. the term 'sexual behavior' encompasses a large spectrum of actions in which humans present their sexuality. previous reports have analyzed the effect of mass disasters on female sexual behavior. many studies in the literature have described the relationship between mass disasters and female sexual behavior, but none have investigated the effect of the sars-cov-2 pandemic on women's sexual attitude. the aim of this study is therefore to evaluate the effect of the sars-cov-2 pandemic on female sexual behavior.

Eligibility criteria:
inclusion criteria: * married * above 18 yo * premenopausal status exclusion criteria: * urinary incontinence * history of gynecologic operation * malignancy * psychiatric or neurologic disease diagnosis * being infected by hbv hcv or hiv
study of specific viral immune responses induced by sars-cov-2 (covid-19)

Conditions: SARS-CoV-2 Infection

Summary: sars-cov-2, has caused an international outbreak of respiratory illness termed covid-19. the investigators used peptides derived from sars-cov-2 virus, to study viral-specific immune responses. cov-crem is a french prospective monocentric study that will evaluate viral-specific cell responses in positive patients for sars-cov-2 on the basis of (rt-pcr) assay performed in respiratory tract sample tested by our local center for disease control.


Eligibility criteria:
inclusion criteria: * covid-19 pcr positive, * hospitalized patients with illness of any duration, and/or spo2 ≤ 92% on room air. * cohorte c : patients with cancer (hematological malignancies and solid tumors). exclusion criteria: * refusal to participate, * any immunosuppressive therapy (i.e. corticosteroids \>10mg of hydrocortisone or equivalent dose) within 14 days before the planned start of study, * active or chronic hepatitis b or c and/or hiv positive (hiv 1/2 antibodies patients), or a known history of active tuberculosis bacillus, * active autoimmune disease that required a systemic treatment, with the following exceptions: * patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study, * patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study, * prior allogeneic bone marrow transplantation or prior solid organ transplantation, * patients currently exposed to chemotherapy, anti-tumor immunotherapy as anti-pd-1, anti-pd-l1, or anti-ctla4 agent or any immune therapy or biotherapy (except for patients in cohort c), * previous prescribing of biotherapy or treatment for the management of covid-19 is not an exclusion criterion, * patient under guardianship, curatorship or under the protection of justice.
estimation of changes in soft tissue rigidity of the buttocks in sitting under weight bearing compared to sitting without weight bearing

Conditions: Changes in Elasticity Duo to Pressure Ulcers in Buttocks

Summary: estimation of changes in soft tissues elasticity in buttocks in lying down and sitting positions by using ultrasound device. the elasticity of fat and muscle tissues will be measured. may ultrasound exam helps to predict the development of pressure ulcers in buttocks due to continuous sitting.

the purpose of the current new research is to check whether ultrasound device can be used as a tool for assessing the elasticity of the soft tissues in buttocks and measuring the elasticity of these tissues with and without bearing weight on a healthy population to set standards of normal values. the far purpose of the research is to use ultrasound device for predicting the development of pressure ulcers. population and methods: in this study, up to 15 healthy people will participate. each participant will pass ultrasound scans of the buttocks, lying down and sitting on a chair designed for the purpose of research and this after signing an informed consent form. the process: 1. the participant lies on his stomach on a bed to determine the location of the muscle that will be marked by a marker.by ultrasound, the investigator measures the thickness of fat and muscle tissues between the ischial tuberosity (its) and the skin. 2. the participant sits without bearing weight on a chair built for this study, the seat is constructed from five straps. non-weight bearing test is when the straps are far from the test area, the transducer is placed on the marked place, thickness and elasticity of muscle tissue and fat will be measured. 3. the participant sits with bearing weight on the chair. weight bearing test is when the straps are close to the test area , the transducer is placed on the marked place, thickness and elasticity of muscle tissue and fat will be measured. after measuring the elasticity of the soft tissues,the data will be analyzed in order to define ranges of differences between elasticity with and without weight bearing.

Eligibility criteria:
inclusion criteria: healthy volunteers, bmi- 18.5-29.9, - exclusion criteria: * people with neurological deficit * people with diabetes * people with a bmi above 29.9 or below 18.5 * pregnant women * people with bedsores * mental incompetence.

Keywords: elastography buttocks ultrasound soft tissue
valproic acid and platinum-based chemoradiation in locally advanced head and neck squamous cell carcinoma

Conditions: Head and Neck Cancer; Oral Cavity Cancer; Oropharyngeal Cancer

Summary: the purpose of this study is to evaluate if the addition of valproic acid to standard platinum-based chemoradiation as definitive treatment of locally advanced head and neck squamous cell carcinoma can improve treatment outcomes, such as response rate.

valproic acid is a known histone deacetylase inhibitor. in addition to activating apoptosis pathways, cell differentiation and downregulating expression of growth factors, it also promotes radiosensitization. most patients with head and neck squamous cell carcinoma are diagnosed with locally advanced disease, in which long term disease control is still a challenge. the incorporation of epigenetic regulation into standard treatment could improve results of definitive platinum-based chemoradiation in such patients.

Eligibility criteria:
inclusion criteria: * unresectable oropharyngeal or oral cavity squamous cell carcinoma * candidate for definitive chemoradiation * no previous treatment * measurable disease according to recist v 1.1 * previous neoplasia, other than head and neck, with more than five years without evidence of disease; basocellular carcinoma of the skin and in situ cervical dysplasia if resected * age under 60 years * ecog performance status 0-2 * ability of understanding and giving informed consent * adequate renal and hepatic function * adequate bone marrow function * normal serum magnesium * absence of qtc prolongation * life expectancy of over 12 weeks exclusion criteria: * pregnancy * distant metastasis * hypersensibility to valproic acid or other antiepileptic drugs * valproic acid chronic use * severe neurologic impairment * uncontrolled comorbidity * hypoalbuminemia * known history of hepatitis b, c or hiv

Keywords: head and neck cancer oropharyngeal cancer oral cavity cancer chemoradiation valproic acid histone deacetylase
percutaneous administration of sirolimus in the treatment of superficial complicated vascular anomalies

Conditions: Kaposiform Hemangioendothelioma; Tufted Angioma; Superficial Vascular Anomalies; Superficial Lymphatic Malformations

Summary: in this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.

vascular anomaly is a kind of rare disease. according to histology, biological behavior and clinical manifestations, it can be divided into two categories: vascular tumor and vascular malformation. mtor inhibitors are proved with the properties of anti-proliferation and anti-angiogenesis. therefore, they have been used in the treatment of vascular anomalies. sirolimus, by its ability to prevent downstream protein synthesis and subsequent cell proliferation and angiogenesis, has become a novel and effective treatment. however, after the children reach complete response, there may still be skin manifestations that affect the appearance and cause psychological shadows. therefore, intervention is required. studies have reported that topical sirolimus is effective in treating kaposiform hemangioendothelioma (khe). it is absorbed through the skin, avoiding the first pass elimination effect of the liver. fewer adverse reactions have been observed. in this study, we investigate the efficacy and safety of percutaneous administration of sirolimus in the treatment of superficial complicated vascular anomalies.

Eligibility criteria:
inclusion criteria: * participant clinically or pathologically diagnosed with khe, ta or complicated superficial vascular anomolies involving lymphatic components. 1. the case is initial, with a relatively limited superficial lesion. 2. the participant has residual surface lesions after oral medication. * participant with no use of other medication or surgical treatment * participant with detailed medical records of the disease at the time of screening * participant with signed and dated informed consent from the guardian(s) exclusion criteria: * participants with kasabach-merritt phenomenon, with platelets \<50×10 9 /l. * participants with general disease such as hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency. * participants with other hematological diseases or solid tumor. * participants allergic to sirolimus or dressing.
postoperative pain after using reciprocating motion with reciproc files versus adaptive motion with twisted file adaptive

Conditions: Postoperative Pain

Summary: assess the effect of using reciprocating motion with reciproc files versus adaptive motion using twisted file adaptive on postoperative pain after instrumentation of necrotic mandibular molars.

in root canal treatment of mandibular molar teeth in patients having necrotic pulp with symptomatic or asymptomatic apical periodontitis, is there difference in postoperative pain after instrumentation between two different kinematics; adaptive motion using twisted file adaptive and reciprocation motion using reciproc

Eligibility criteria:
inclusion criteria: 1. patients who are medically free from any systemic disease that may contraindicate our interventions. 2. patient's age between 18-60 years old. 3. mandibular molars having necrotic pulps with symptomatic or asymptomatic apical periodontitis because this group of patients may have more postoperative pain than vital teeth22. 4. positive patient's acceptance for participation in the study. exclusion criteria: 1. patients who had used any type of analgesic medication during the preceding 12 hours before the treatment to give true response of pain after instrumentation. 2. teeth with vital pulps or symptomatic irreversible pulpitis. 3. pregnant patients or lactating because of radiographic hazards and use of analgesics27. 4. any known sensitivity or adverse reactions to ibuprofen.

Keywords: postoperative pain reciproc twisted file adaptive
effectiveness of a wechat-based alcohol consumption intervention mini-program ("sober time act") in china

Conditions: Alcohol Use Disorder; Alcohol Abuse

Summary: the purpose of this study is to explore whether "sober time act", a digital intervention tool for alcohol use developed based on wechat mini program, is effective in improving risky alcohol use among chinese local drinkers.


Eligibility criteria:
inclusion criteria: * above the age of 18 * the total score in line with the audit scale ≧8 * provide at least one backup contact information * non-illiterate, able to use smart phones without barriers * wechat version support small program function (6.5.3 and above) * understand the nature of this study and sign the informed consent exclusion criteria: * other interventions and treatments to reduce alcohol use were given during the trial * severe primary or secondary cognitive dysfunction, unable to complete the screening scale and baseline questionnaire

Keywords: hazardous drinking alcohol use disorders, auds wechat-based digital intervention randomized controlled trial mixed methods approach
assessment of neuroinflammation in central inflammatory disorders using [f-18]dpa-714.

Conditions: Fibromyalgia; Chronic Fatigue Syndrome; Multiple Sclerosis; Healthy

Summary: the primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the pet radiopharmaceutical \[f-18\]dpa-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. the pet tracer \[f-18\]dpa-714 binds to the 18 kda translocator protein (tspo, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. the primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than hc individuals as measured with \[f-18\]dpa-714-pet/mri.


Eligibility criteria:
inclusion criteria: 1. 18 to 65 years of age 2. healthy volunteer or clinical diagnosis of multiple sclerosis (ms) or meets 2016 american college of rheumatology (acr) case definition criteria for fibromyalgia or meets 1994 fukuda case definition criteria for chronic fatigue syndrome exclusion criteria: 1. contraindication to mri 2. pregnancy 3. lactation 4. individuals who are unable to participate in the imaging portion due to severity of their medical condition 5. chronic infectious disease (e.g. hiv, hcv) 6. viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation 7. diagnosis of cancer, including leukemia 8. blood or blood clotting disorder 9. except for individuals with ms, a diagnosis of autoimmune disease is exclusionary 10. positive urine β-hcg test day of procedure or a serum -hcg test within 48 hours prior to the administration of \[18f\]dpa-714 11. currently enrolled in a clinical trial utilizing experimental therapies
a study of bevacizumab (avastin) versus placebo in combination with capecitabine (xeloda) and cisplatin as first-line therapy for advanced gastric cancer

Conditions: Gastric Cancer

Summary: this 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer. participants will be randomized to one of two treatment groups bevacizumab + capecitabine/cisplatin (experimental arm) or placebo + capecitabine/cisplatin (control arm).


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable, locally advanced or metastatic disease, not amenable to curative therapy * eastern cooperative oncology group (ecog) performance status of 0,1 or 2 * measurable disease or non-measurable but evaluable disease, according to the response evaluation criteria in solid tumors (recist) exclusion criteria: * previous chemotherapy for locally advanced or metastatic gastric cancer * previous platinum or anti-angiogenic therapy * radiotherapy within 28 days of randomization * evidence of central nervous system (cns) metastasis at baseline
isokinetic fatigue index in a population of triathletes

Conditions: Musculoskeletal Diseases

Summary: the aim of this study is to evaluate the relevance of carrying out a measure of muscular fatigability by isokinetism, in the search for factors favouring micro-traumatic lesions of the lower limbs in a population of triathletes. this is a prospective monocentric pilot study of the before/after type in which the patient is his or her own control, in high-level triathletes practising an endurance sport, who have had more than 7 consecutive days off running due to a musculoskeletal injury during the previous sporting year.


Eligibility criteria:
inclusion criteria: * having had a practical running break of more than 7 consecutive days due to a musculoskeletal injury of a lower limb during the previous sport year * willing to comply with all study procedures * having given written consent * socially insured exclusion criteria: * pain that does not allow an isokinetic test to be performed * knee joint amplitude less than 100° of flexion or flessum greater than 5°. * history of rupture or ligamentoplasty of the anterior cruciate ligament less than 2 years ago * history of knee surgery less than 2 years